ro 8-0576 has been researched along with 3-methoxytyrosine in 6 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (3-methoxytyrosine) | Trials (3-methoxytyrosine) | Recent Studies (post-2010) (3-methoxytyrosine) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 186 | 34 | 27 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boomsma, F; Hovestadt, A; Man in't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Da Prada, M; Haefely, WE; Kettler, R; Schaffner, R; Zürcher, G | 1 |
| Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP | 1 |
| Himori, N; Mishima, K | 1 |
| Akaike, N; Himori, N; Kurasawa, M; Mishima, K; Tanaka, Y | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
1 trial(s) available for ro 8-0576 and 3-methoxytyrosine
| Article | Year |
|---|---|
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
5 other study(ies) available for ro 8-0576 and 3-methoxytyrosine
| Article | Year |
|---|---|
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Phenytoin; Time Factors; Tyrosine | 1989 |
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Topics: Administration, Oral; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Carbidopa; Delayed-Action Preparations; Dihydroxyphenylalanine; Dogs; Dopa Decarboxylase; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Kidney; Levodopa; Liver; Male; Mice; Rats; Time Factors; Tyrosine | 1987 |
Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Topics: Adult; Antacids; Benserazide; Biological Availability; Delayed-Action Preparations; Drug Combinations; Eating; Gastric Mucosa; Humans; Hydrazines; Levodopa; Middle Aged; Stomach; Tyrosine | 1987 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Synergism; Haloperidol; Kinetics; Levodopa; Male; Mice; Mice, Inbred C57BL; Nitrophenols; Tolcapone; Tyrosine | 1994 |
3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Topics: Animals; Benserazide; Catalepsy; Drug Combinations; Haloperidol; Levodopa; Male; Mice; Motor Activity; Tyrosine | 1994 |